TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $37.63 million. The enterprise value is $65.12 million.
| Market Cap | 37.63M |
| Enterprise Value | 65.12M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 45.14 million shares outstanding. The number of shares has increased by 36.23% in one year.
| Current Share Class | 45.14M |
| Shares Outstanding | 45.14M |
| Shares Change (YoY) | +36.23% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 7.64% |
| Owned by Institutions (%) | 23.20% |
| Float | 21.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.46 |
| Forward PS | 0.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.99
| Current Ratio | 2.99 |
| Quick Ratio | 2.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.88 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.40% |
| Return on Invested Capital (ROIC) | -45.05% |
| Return on Capital Employed (ROCE) | -81.91% |
| Weighted Average Cost of Capital (WACC) | 10.38% |
| Revenue Per Employee | $366,550 |
| Profits Per Employee | -$188,894 |
| Employee Count | 218 |
| Asset Turnover | 1.26 |
| Inventory Turnover | 2.26 |
Taxes
In the past 12 months, TELA Bio has paid $265,000 in taxes.
| Income Tax | 265,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.21% in the last 52 weeks. The beta is 1.36, so TELA Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -50.21% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 59.48 |
| Average Volume (20 Days) | 312,063 |
Short Selling Information
The latest short interest is 338,486, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 338,486 |
| Short Previous Month | 341,493 |
| Short % of Shares Out | 0.75% |
| Short % of Float | 1.56% |
| Short Ratio (days to cover) | 2.67 |
Income Statement
In the last 12 months, TELA Bio had revenue of $79.91 million and -$41.18 million in losses. Loss per share was -$0.78.
| Revenue | 79.91M |
| Gross Profit | 54.57M |
| Operating Income | -34.01M |
| Pretax Income | -40.91M |
| Net Income | -41.18M |
| EBITDA | -33.01M |
| EBIT | -34.01M |
| Loss Per Share | -$0.78 |
Balance Sheet
The company has $30.42 million in cash and $57.92 million in debt, with a net cash position of -$27.49 million or -$0.61 per share.
| Cash & Cash Equivalents | 30.42M |
| Total Debt | 57.92M |
| Net Cash | -27.49M |
| Net Cash Per Share | -$0.61 |
| Equity (Book Value) | -15.87M |
| Book Value Per Share | -0.35 |
| Working Capital | 36.27M |
Cash Flow
In the last 12 months, operating cash flow was -$31.14 million and capital expenditures -$480,000, giving a free cash flow of -$31.62 million.
| Operating Cash Flow | -31.14M |
| Capital Expenditures | -480,000 |
| Depreciation & Amortization | 1.00M |
| Net Borrowing | 17.58M |
| Free Cash Flow | -31.62M |
| FCF Per Share | -$0.70 |
Margins
Gross margin is 68.29%, with operating and profit margins of -42.56% and -51.53%.
| Gross Margin | 68.29% |
| Operating Margin | -42.56% |
| Pretax Margin | -51.20% |
| Profit Margin | -51.53% |
| EBITDA Margin | -41.31% |
| EBIT Margin | -42.56% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.23% |
| Shareholder Yield | -36.23% |
| Earnings Yield | -111.04% |
| FCF Yield | -85.26% |
Analyst Forecast
The average price target for TELA Bio is $2.10, which is 151.95% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.10 |
| Price Target Difference | 151.95% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 6.34% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -9.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.29 |
| Piotroski F-Score | 3 |